ROS1 and breast carcinoma: This fusion leads to aberrant activation of ROS1 tyrosine kinase, rendering patients highly susceptible to ROS1 inhibitors.[40] LAMP3 is involved in the autophagic process and has been shown to contribute to tamoxifen resistance in breast cancer.